Citius Pharmaceuticals (CTXR) 10-Q 10 Feb 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Dec. 31, 2022	Feb. 10, 2023
Document Information Line Items
Entity Registrant Name	Citius Pharmaceuticals, Inc.
Trading Symbol	CTXR
Document Type	10-Q
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		146,257,797
Amendment Flag	false
Entity Central Index Key	0001506251
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38174
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	27-3425913
Entity Address, Address Line One	11 Commerce Drive
Entity Address, Address Line Two	First Floor
Entity Address, City or Town	Cranford
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07016
City Area Code	(908)
Local Phone Number	967-6677
Title of 12(b) Security	Common stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Current Assets:
Cash and cash equivalents	$ 36,887,251	$ 41,711,690
Prepaid expenses	5,430,125	2,852,580
Total Current Assets	42,317,376	44,564,270
Property and equipment, net	3,370	4,100
Operating lease right-of-use asset, net	599,617	646,074
Other Assets:
Deposits	38,062	38,062
In-process research and development	59,400,000	59,400,000
Goodwill	9,346,796	9,346,796
Total Other Assets	68,784,858	68,784,858
Total Assets	111,705,221	113,999,302
Current Liabilities:
Accounts payable	1,537,578	1,165,378
Accrued expenses	690,402	1,405,394
Accrued compensation	2,107,014	1,762,251
Operating lease liability	202,178	196,989
Total Current Liabilities	4,537,172	4,530,012
Deferred tax liability	5,705,800	5,561,800
Operating lease liability – noncurrent	428,568	481,245
Total Liabilities	10,671,540	10,573,057
Commitments and Contingencies
Stockholders’ Equity:
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 146,211,130 shares issued and outstanding at December 31, 2022 and September 30, 2022	146,211	146,211
Additional paid-in capital	233,569,202	232,368,121
Accumulated deficit	(133,282,112)	(129,688,467)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity	100,433,301	102,825,865
Non-controlling interest	600,380	600,380
Total Equity	101,033,681	103,426,245
Total Liabilities and Equity	$ 111,705,221	$ 113,999,302

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Dec. 31, 2022	Sep. 30, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	146,211,130	146,211,130
Common stock, shares outstanding	146,211,130	146,211,130

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues
Operating Expenses
Research and development	3,445,515	5,457,849
General and administrative	2,603,287	2,896,749
Stock-based compensation – general and administrative	1,201,081	904,604
Total Operating Expenses	7,249,883	9,259,202
Operating Loss	(7,249,883)	(9,259,202)
Other Income
Interest income	214,549	33,982
Gain on sale of New Jersey net operating losses	3,585,689
Total Other Income	3,800,238	33,982
Loss before Income Taxes	(3,449,645)	(9,225,220)
Income tax expense	144,000
Net Loss	$ (3,593,645)	$ (9,225,220)
Net Loss Per Share - Basic (in Dollars per share)	$ (0.02)	$ (0.06)
Weighted Average Common Shares Outstanding
Basic (in Shares)	146,211,130	146,012,169

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net Loss Per Share - Diluted	$ (0.02)	$ (0.06)
Diluted	146,211,130	146,012,169

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total Citius Pharmaceuticals, Inc. Shareholder’s Equity	Non-Controlling Interest	Total
Balance at Sep. 30, 2021		$ 145,979	$ 228,084,195	$ (96,047,821)	$ 132,182,353	$ 600,380	$ 132,782,733
Balance (in Shares) at Sep. 30, 2021		145,979,429
Issuance of common stock for services		$ 50	95,834		95,884		95,884
Issuance of common stock for services (in Shares)		50,201
Stock-based compensation expense			904,604		904,604		904,604
Net loss				(9,225,220)	(9,225,220)		(9,225,220)
Balance at Dec. 31, 2021		$ 146,029	229,084,633	(105,273,041)	123,957,621	600,380	124,558,001
Balance (in Shares) at Dec. 31, 2021		146,029,630
Balance at Sep. 30, 2022		$ 146,211	232,368,121	(129,688,467)	102,825,865	600,380	103,426,245
Balance (in Shares) at Sep. 30, 2022		146,211,130
Stock-based compensation expense			1,201,081		1,201,081		1,201,081
Net loss				(3,593,645)	(3,593,645)		(3,593,645)
Balance at Dec. 31, 2022		$ 146,211	$ 233,569,202	$ (133,282,112)	$ 100,433,301	$ 600,380	$ 101,033,681
Balance (in Shares) at Dec. 31, 2022		146,211,130

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows From Operating Activities:
Net loss	$ (3,593,645)	$ (9,225,220)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,201,081	904,604
Issuance of common stock for services		95,884
Amortization of operating lease right-of-use asset	46,457	42,879
Depreciation	730	730
Deferred income tax expense	144,000
Changes in operating assets and liabilities:
Prepaid expenses	(2,577,545)	217,852
Accounts payable	372,200	512,108
Accrued expenses	(714,992)	2,514,649
Accrued compensation	344,763	327,690
Operating lease liability	(47,488)	(42,698)
Net Cash Used In Operating Activities	(4,824,439)	(4,651,522)
Net Cash Used In Investing Activities
Net Cash Provided By Financing Activities
Net Change in Cash and Cash Equivalents	(4,824,439)	(4,651,522)
Cash and Cash Equivalents - Beginning of Period	41,711,690	70,072,946
Cash and Cash Equivalents - End of Period	$ 36,887,251	$ 65,421,424

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2022
Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies[Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Citius Pharmaceuticals, Inc. (“Citius,” the “Company,” “we” or “us”) is a late-stage pharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products and stem cell therapies. On March 30, 2016, Citius acquired Leonard-Meron Biosciences, Inc. (“LMB”) as a wholly-owned subsidiary by issuing shares of its common stock. On September 11, 2020, we formed NoveCite, Inc. (“NoveCite”), a Delaware corporation, of which we own 75% (7,500,000 shares) of the issued and outstanding capital stock (see Note 3). On August 23, 2021, we formed Citius Acquisition Corp. (“Citius Acq.”), as a wholly-owned subsidiary in conjunction with the acquisition of I/ONTAK, which began operations in April 2022. In-process research and development (“IPR&D”) consists of (i) the $19,400,000 acquisition value of LMB’s drug candidate Mino-Lok®, which is an antibiotic solution used to treat catheter-related bloodstream infections and is expected to be amortized on a straight-line basis over a period of eight years commencing upon revenue generation, and (ii) the $40,000,000 acquisition value of the exclusive license for I/ONTAK (denileukin diftitox), which is a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma, and is expected to be amortized on a straight-line basis over a period of twelve years commencing upon revenue generation. Goodwill of $9,346,796 represents the value of LMB’s industry relationships and its assembled workforce. Goodwill will not be amortized but will be tested at least annually for impairment. Citius is subject to a number of risks common to companies in the pharmaceutical industry including, but not limited to, risks related to the development by Citius or its competitors of research and development stage product candidates, market acceptance of its product candidates that might be approved, competition from larger companies, dependence on key personnel, dependence on key suppliers and strategic partners, the Company’s ability to obtain additional financing and the Company’s compliance with governmental and other regulations. Basis of Presentation and Summary of Significant Accounting Policies Basis of Preparation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state the condensed consolidated financial position of the Company as of December 31, 2022, and the results of its operations and cash flows for the three months ended December 31, 2022 and 2021. The operating results for the three months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022 filed with the Securities and Exchange Commission (“SEC”). Use of Estimates Basic and Diluted Net Loss per Common Share Recently Issued Accounting Standards In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities.

Liquidity and Management's Plan

Liquidity and Management's Plan	3 Months Ended
	Dec. 31, 2022
Liquidity and Managements Plan [Abstract]
LIQUIDITY AND MANAGEMENT'S PLAN	2. LIQUIDITY AND MANAGEMENT’S PLAN The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company experienced negative cash flows from operations of $4,824,439 for the three months ended December 31, 2022. As a result of the Company’s common stock offerings and common stock warrant exercises during the year ended September 30, 2021, the Company had working capital of approximately $37,800,000 at December 31, 2022. The Company estimates that its available cash resources will be sufficient to fund its operations through February 2024. The Company has generated no operating revenue to date and has principally raised capital through the issuance of debt and equity instruments to finance its operations. However, the Company’s continued operations beyond February 2024

Patent and Technology License A

Patent and Technology License Agreements	3 Months Ended
	Dec. 31, 2022
Patent and Technology License Agreements [Abstract]
PATENT AND TECHNOLOGY LICENSE AGREEMENTS	3. PATENT AND TECHNOLOGY LICENSE AGREEMENTS Patent and Technology License Agreement – Mino-Lok LMB has a patent and technology license agreement with Novel Anti-Infective Therapeutics, Inc. (“NAT”) to develop and commercialize Mino-Lok on an exclusive, worldwide sub licensable basis, as amended. LMB pays an annual maintenance fee each June until commercial sales of a product subject to the license commence. The Company recorded an annual maintenance fee of $90,000 in June 2022 and 2021. LMB will also pay annual royalties on net sales of licensed products, with royalties ranging from the mid-single digits to the low double digits. In limited circumstances in which the licensed product is not subject to a valid patent claim and a competitor is selling a competing product, the royalty rate is in the low- to mid-single digits. After a commercial sale is obtained, LMB must pay minimum aggregate annual royalties of $100,000 in the first commercial year which is prorated for a less than 12-month period, increasing $25,000 per year to a maximum of $150,000 annually. LMB must also pay NAT up to an aggregate of $1,100,000 upon achieving specified regulatory and sales milestones. Finally, LMB must pay NAT a specified percentage of payments received from any sub-licensees. Unless earlier terminated by NAT, based on the failure to achieve certain development and commercial milestones, the license agreement remains in effect until the date that all patents licensed under the agreement have expired and all patent applications within the licensed patent rights have been cancelled, withdrawn, or expressly abandoned. Patent and Technology License Agreement – Mino-Wrap On January 2, 2019, we entered into a patent and technology license agreement with the Board of Regents of the University of Texas System on behalf of the University of Texas M. D. Anderson Cancer Center (“Licensor”), whereby we in-licensed exclusive worldwide rights to the patented technology for any and all uses relating to breast implants. We intend to develop Mino-Wrap as a liquefying gel-based wrap containing minocycline and rifampin for the reduction of infections associated with breast implants following breast reconstructive surgeries. We are required to use commercially reasonable efforts to commercialize Mino-Wrap under several regulatory scenarios and achieve milestones associated with these regulatory options leading to an approval from the U.S. Food and Drug Administration (“FDA”). Under the license agreement, the Company paid an annual maintenance fee of $60,000 and $45,000 in January 2022 and 2021, respectively. The annual maintenance fee increases by $15,000 per year up to a maximum of $90,000. Annual maintenance fees cease on the first sale of product. We also must pay up to an aggregate of $2.1 million in milestone payments, contingent on the achievement of various regulatory and commercial milestones. Under the terms of the license agreement, we also must pay a royalty of mid- to upper-single digit percentages of net sales, depending on the amount of annual sales, and subject to downward adjustment to lower- to mid-single digit percentages in the event there is no valid patent for the product in the United States at the time of sale. After the first sale of product, we will owe an annual minimum royalty payment of $100,000 that will increase annually by $25,000 for the duration of the term. We will be responsible for all patent expenses incurred by Licensor for the term of the agreement although Licensor is responsible for the filing, prosecution and maintenance of all patents. Unless earlier terminated by Licensor, based upon the failure by us to achieve certain development and commercial milestones or for various breaches by us, the agreement expires on the later of the expiration of the patents or January 2, 2034. License Agreement with Novellus On October 6, 2020, our subsidiary, NoveCite, signed an exclusive license agreement with subsidiary of Novellus Inc. (“Novellus”). Upon execution of the license agreement, we paid $5,000,000 to Novellus, which was charged to research and development expense during the year ended September 30, 2021, and issued Novellus shares of NoveCite’s common stock representing 25% of the outstanding equity. We own the other 75% of NoveCite’s outstanding equity. Pursuant to the terms of the original stock subscription agreement between Novellus and NoveCite, if NoveCite issued additional equity, subject to certain exceptions, NoveCite had to maintain Novellus’s ownership at 25% by issuing additional shares to Novellus. In July 2021, Novellus was acquired by Brooklyn ImmunoTherapeutics, Inc. (“Brooklyn”). In connection with that transaction, the stock subscription agreement between Novellus and NoveCite was amended to assign to Brooklyn all of Novellus’s right, title, and interest in the stock subscription agreement and delete the anti-dilution protection and replace it with a right of first refusal whereby Brooklyn will have the right to purchase all or a portion of the securities that NoveCite intends to sell or in the alternative, at the option of NoveCite, Brooklyn may purchase that amount of the securities proposed to be sold by NoveCite to allow Brooklyn to maintain its then percentage ownership. In October 2022, Brooklyn changed its name to Eterna Therapeutics Inc. (“Eterna”). Citius is responsible for the operational activities of NoveCite and bears all costs necessary to operate NoveCite. Citius’s officers are also the officers of NoveCite and oversee the business strategy and operations of NoveCite. As such, NoveCite is accounted for as a consolidated subsidiary with a noncontrolling interest. Eterna has no contractual rights in the profits or obligations to share in the losses of NoveCite, and the Company has not allocated any losses to the noncontrolling interest. NoveCite is obligated to pay Novellus up to $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) the date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Eterna an amount equal to a mid-twenties percentage of any sublicensee fees it receives. Under the terms of the license agreement, if Eterna receives any revenue involving the original cell line included in the licensed technology, then Eterna shall remit to NoveCite 50% of such revenue. The term of the license agreement continues on a country-by-country and licensed product-by-licensed product basis until the expiration of the last-to-expire royalty term. Either party may terminate the license agreement upon written notice if the other party is in material default. NoveCite may terminate the license agreement at any time without cause upon 90 days prior written notice. Eterna will be responsible for preparing, filing, prosecuting, and maintaining all patent applications and patents included in the licensed patents in the territory, provided however, that if Eterna decides that it is not interested in maintaining a particular licensed patent or in preparing, filing, or prosecuting a licensed patent, NoveCite will have the right, but not the obligation, to assume such responsibilities in the territory at NoveCite’s sole cost and expense. License Agreement with Eisai In September 2021, the Company entered into a definitive agreement with Dr. Reddy’s Laboratories SA, a subsidiary of Dr. Reddy’s Laboratories, Ltd. (collectively, “Dr. Reddy’s”) to acquire its exclusive license of I/ONTAK (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. Under the terms of this agreement, Citius acquired Dr. Reddy’s exclusive license of I/ONTAK from Eisai Co., Ltd. (“Eisai”) and other related assets owned by Dr. Reddy’s. Citius’s exclusive license include rights to develop and commercialize I/ONTAK in all markets except for Japan and certain parts of Asia. Additionally, Citius retained an option on the right to develop and market the product in India. Eisai retains exclusive development and marketing rights for denileukin diftitox in Japan and most Asian countries. Citius paid $40 million upfront payment which represents the acquisition date fair value of the in-process research and development acquired from Dr. Reddy’s. Dr. Reddy’s is entitled to up to $40 million in development milestone payments related to CTCL approvals in the U.S. and other markets, up to $70 million in development milestones for additional indications, as well as commercial milestone payments and low double-digit tiered royalties on net product sales, and up to $300 million for commercial sales milestones. We also must pay on a fiscal quarter basis tiered royalties equal to low double-digit percentages of net product sales. The royalties will end on the earlier of (i) the 15-year anniversary of the first commercial sale of the latest indication that received regulatory approval in the applicable country and (ii) the date on which a biosimilar product results in the reduction of net sales in the applicable product by 50% in two consecutive quarters, as compared to the four quarters prior to the first commercial sale of the biosimilar product. We will also pay to Dr. Reddy’s an amount equal to a low-thirties percentage of any sublicense upfront consideration or milestone payments (or the like) received by us and the greater of (i) a low-thirties percentage of any sublicensee sales-based royalties or (ii) a mid-single digit percentage of such licensee’s net sales. Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a biologics license application (“BLA”) for I/ONTAK. Eisai will be responsible for completing the current CTCL clinical trial, and chemistry, manufacturing, and controls (CMC) activities through the filing of the BLA for I/ONTAK with the FDA (which was filed in September 2022). Citius will be responsible for development costs associated with potential additional indications. The term of the license agreement will continue until (i) if there has not been a commercial sale of a licensed product in the territory, until the 10-year anniversary of the original license effective date, March 30, 2016, or (ii) if there has been a first commercial sale of a licensed product in the territory within the 10-year anniversary of the original license effective date, the 10-year anniversary of the first commercial sale on a country-by-country basis. The term of the license may be extended for additional 10-year periods for all countries in the territory by notifying Eisai and paying an extension fee equal to $10 million. Either party may terminate the license agreement upon written notice if the other party is in material breach of the agreement, subject to cure within the designated time periods. Either party also may terminate the license agreement immediately upon written notice if the other party files for bankruptcy or takes related actions or is unable to pay its debts as they become due. Additionally, either party will have the right to terminate the agreement if the other party directly or indirectly challenges the patentability, enforceability or validity of any licensed patent. Also under the agreement with Dr. Reddy’s, we are required to (i) use commercially reasonable efforts to make commercially available products in the CTCL indication, (ii) initiate two investigator initiated immuno-oncology trials (which we initiated in June 2021 and September 2022, respectively), (iii) use commercially reasonable efforts to achieve each of the approval milestones, and (iv) complete each specified immuno-oncology investigator trial on or before the four-year anniversary of the effective date of the definitive agreement. Additionally, we are required to commercially launch a product in a territory within six months of receiving regulatory approval for such product in each such jurisdiction.

Common Stock, Stock Options and

Common Stock, Stock Options and Warrants	3 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
COMMON STOCK, STOCK OPTIONS AND WARRANTS	4. COMMON STOCK, STOCK OPTIONS AND WARRANTS Common Stock Issued for Services On November 2, 2021, the Company issued 50,201 shares of common stock for investor relations services and expensed the $95,884 fair value of the common stock issued. On March 21, 2022, the Company issued 100,000 shares of common stock for media, public and investor relations services and expensed the $178,000 fair value of the common stock issued. On September 13, 2022, the Company issued 81,500 shares of common stock for media, public and investor relations services and expensed the $104,320 fair value of the common stock issued. Stock Option Plans Under our 2014 Stock Incentive Plan, we reserved 866,667 common shares for issuance to employees, directors and consultants. As of December 31, 2022, options to purchase 855,171 shares were outstanding and no shares remain available for future grants. Under our 2018 Omnibus Stock Incentive Plan and we reserved 2,000,000 common shares for issuance to employees, directors and consultants. As of December 31, 2022, options to purchase 1,820,000 shares were outstanding and no shares remain available for future grants. Under our 2020 Omnibus Stock Incentive Plan and we reserved 3,110,000 common shares for issuance to employees, directors, and consultants. As of December 31, 2022, options to purchase 1,870,000 shares were outstanding and the remaining 1,240,000 shares were transferred to the 2021 Omnibus Stock Incentive Plan (“2021 Stock Plan”). Under our 2021 Omnibus Stock Incentive Plan and we reserved 8,740,000 shares for issuance to employees, directors, and consultants through options, SARs, dividend equivalent rights, restricted stock, restricted stock units, or other rights. As of December 31, 2022, options to purchase 8,705,000 shares were outstanding and 35,000 shares were available for future grants. In November 2022, our Board approved the Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan (the “2023 Stock Plan”), subject to stockholder approval, which was received on February 7, 2023. The 2023 Stock Plan has reserved for issuance 12,000,000 shares of our common stock plus the 35,000 shares that remained available under the 2021 Stock Plan on February 7, 2023. As of the effective date of the 2023 Stock Plan, there were no more shares available for grant under the 2021 Stock Plan. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The expected term of stock options granted, all of which qualify as “plain vanilla,” is based on the average of the contractual term (generally 10 years) and the vesting period. For non-employee options, the expected term is the contractual term. A summary of option activity under our stock option plans (excluding the NoveCite 2020 Omnibus Stock Incentive Plan) is presented below: Option Weighted- Weighted- Aggregate Outstanding at October 1, 2022 9,400,171 $ 2.07 7.81 years $ 869,509 Granted 3,850,000 1.25 Exercised — — Forfeited or expired — — Outstanding at December 31, 2022 13,250,171 $ 1.83 8.20 years $ 169,237 Exercisable at December 31, 2022 6,057,254 $ 2.18 6.96 years $ 169,237 On October 4, 2022, the Board of Directors granted options to purchase 3,375,000 shares to employees, 375,000 shares to directors and 50,000 shares to a consultant at $1.25 per share. On November 8, 2022, the Board of Directors granted options to purchase 50,000 shares to a consultant at $1.04 per share. The weighted average grant date fair value of the options granted during the three months ended December 31, 2022 was estimated at $0.97 per share. All of these options vest over terms of 12 to 36 months and have a term of 10 years. On October 11, 2021, the Board of Directors granted options to purchase 2,515,000 shares to employees, 375,000 shares to directors and 175,000 shares to consultants at $2.04 per share. On November 1, 2021, the Board of Directors granted options to purchase 200,000 shares to an employee at $1.87 per share. The weighted average grant date fair value of the options granted during the three months ended December 31, 2021 was estimated at $1.72 per share. All of these options vest over terms of 12 to 36 months and have a term of 10 years. Stock-based compensation expense for the three months ended December 31, 2022 and 2021 was $1,201,081 (including $33,333 for the NoveCite Stock Plan) and $904,604 (including $33,333 for the NoveCite Stock Plan), respectively. At December 31, 2022, unrecognized total compensation cost related to unvested awards under the Citius stock plans of $7,877,302 is expected to be recognized over a weighted average period of 2.1 years. Under the NoveCite Stock Plan, we reserved 2,000,000 common shares of NoveCite for issuance. The NoveCite Stock Plan provides incentives to employees, directors, and consultants through grants of options, SARs, dividend equivalent rights, restricted stock, restricted stock units, or other rights. As of December 31, 2022, there were options outstanding to purchase 2,000,000 common shares of NoveCite and no shares available for future grants. As of December 31, 2022, NoveCite has options outstanding to purchase 2,000,000 common shares at a weighted average exercise price of $0.24 per share, of which 1,251,111 are exercisable. All of these options vest over 36 months and have a term of 10 years. The weighted average remaining contractual term of options outstanding under the NoveCite Stock Plan is 8.1 years. At December 31, 2022, unrecognized total compensation cost related to unvested awards under the NoveCite Stock Plan of $149,777 is expected to be recognized over a weighted average period of 1.2 years. Warrants As of December 31, 2022, we have reserved shares of common stock for the exercise of outstanding warrants as follows: Exercise Number Expiration Date December 2017 Registered Direct/Private Placement Investors $ 4.63 640,180 June 19, 2023 March 2018 Registered Direct/Private Placement Investors 2.86 218,972 October 2, 2023 March 2018 Registered Direct/Private Placement Agent 3.73 46,866 March 28, 2023 August 2018 Offering Investors 1.15 3,921,569 August 14, 2023 August 2018 Offering Agent 1.59 189,412 August 8, 2023 April 2019 Registered Direct/Private Placement Investors 1.42 1,294,498 April 5, 2024 April 2019 Registered Direct/Private Placement Agent 1.93 240,130 April 5, 2024 September 2019 Offering Investors 0.77 2,793,297 September 27, 2024 September 2019 Offering Underwriter 1.12 194,358 September 27, 2024 February 2020 Exercise Agreement Agent 1.28 138,886 August 19, 2025 May 2020 Registered Direct Offering Investors 1.00 1,670,588 November 18, 2025 May 2020 Registered Direct Offering Agent 1.33 155,647 May 14, 2025 August 2020 Underwriter 1.31 201,967 August 10, 2025 January 2021 Private Placement Investors 1.23 3,091,192 July 27, 2026 January 2021 Private Placement Agent 1.62 351,623 July 27, 2026 February 2021 Offering Investors 1.70 20,580,283 February 19, 2026 February 2021 Offering Agent 1.88 2,506,396 February 19, 2026 38,235,864 At December 31, 2022, the weighted average remaining life of the outstanding warrants is 2.6 years, all warrants are exercisable, and the aggregate intrinsic value of the warrants outstanding was $55,866. Common Stock Reserved A summary of common stock reserved for future issuances as of December 31, 2022 is as follows: Stock plan options outstanding 13,250,171 Stock plan shares available for future grants 35,000 Warrants outstanding 38,235,864 Total 51,521,035

Operating Lease

Operating Lease	3 Months Ended
	Dec. 31, 2022
Operating Lease [Abstract]
OPERATING LEASE	5. OPERATING LEASE Effective July 1, 2019, Citius entered into a 76-month lease for office space in Cranford, NJ. Citius pays its proportionate share of real estate taxes and operating expenses in excess of the base year expenses. These costs are variable lease payments and are not included in the determination of the lease’s right-of-use asset or lease liability. The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company’s lease does not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments based on the remaining lease term as of the adoption date. ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component. ● The expected lease terms include noncancelable lease periods. The elements of lease expense are as follows: Lease cost Three Months Ended Three Months Ended Operating lease cost $ 59,707 $ 59,705 Variable lease cost 1,158 — Total lease cost $ 60,865 $ 59,705 Other information Weighted-average remaining lease term - operating leases 2.8 Years 3.8 Years Weighted-average discount rate - operating leases 8.0 % 8.0 % Maturities of lease liabilities due under the Company’s non-cancellable leases as of December 31, 2022 is as follows: Year Ending September 30, December 31, 2023 (excluding the 3 months ended December 31, 2022) $ 183,427 2024 249,024 2025 253,883 2026 21,460 Total lease payments 707,794 Less: interest (77,048 ) Present value of lease liabilities $ 630,746 Leases Classification December 31, September 30, Assets Lease asset Operating $ 599,617 $ 646,074 Total lease assets $ 599,617 $ 646,074 Liabilities Current Operating $ 202,178 $ 196,989 Non-current Operating 428,568 481,245 Total lease liabilities $ 630,746 $ 678,234 Interest expense on the lease liability was $13,250 and $16,826 for the three months ended December 31, 2022 and 2021, respectively.

Gain on Sale of New Jersey Net

Gain on Sale of New Jersey Net Operating Losses	3 Months Ended
	Dec. 31, 2022
Gain on Sale of New Jersey Net Operating Losses [Abstract]
GAIN ON SALE OF NEW JERSEY NET OPERATING LOSSES	6. GAIN ON SALE OF NEW JERSEY NET OPERATING LOSSES The Company recognized a gain of $3,585,689 for the three months ended December 31, 2022 in connection with the sale of certain New Jersey income tax net operating losses to a third party under the New Jersey Technology Business Tax Certificate Transfer Program.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	7. SUBSEQUENT EVENTS The Company held its annual meeting of stockholders on February 7, 2023. Pursuant to this, the Company’s stockholders approved the 2023 Omnibus Stock Incentive Plan (the “2023 Plan”) which reserved 12,000,000 shares plus the 35,000 remaining shares from the 2021 Omnibus Stock Incentive Plan for a maximum of 12,035,000 shares in total.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state the condensed consolidated financial position of the Company as of December 31, 2022, and the results of its operations and cash flows for the three months ended December 31, 2022 and 2021. The operating results for the three months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022 filed with the Securities and Exchange Commission (“SEC”).
Use of Estimates	Use of Estimates
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share
Recently Issued Accounting Standards	Recently Issued Accounting Standards In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities.

Common Stock, Stock Options a_2

Common Stock, Stock Options and Warrants (Tables)	3 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of summary of option activity under our stock option plans	Option Weighted- Weighted- Aggregate Outstanding at October 1, 2022 9,400,171 $ 2.07 7.81 years $ 869,509 Granted 3,850,000 1.25 Exercised — — Forfeited or expired — — Outstanding at December 31, 2022 13,250,171 $ 1.83 8.20 years $ 169,237 Exercisable at December 31, 2022 6,057,254 $ 2.18 6.96 years $ 169,237
Schedule of reserved shares of common stock for the exercise of outstanding warrants	Exercise Number Expiration Date December 2017 Registered Direct/Private Placement Investors $ 4.63 640,180 June 19, 2023 March 2018 Registered Direct/Private Placement Investors 2.86 218,972 October 2, 2023 March 2018 Registered Direct/Private Placement Agent 3.73 46,866 March 28, 2023 August 2018 Offering Investors 1.15 3,921,569 August 14, 2023 August 2018 Offering Agent 1.59 189,412 August 8, 2023 April 2019 Registered Direct/Private Placement Investors 1.42 1,294,498 April 5, 2024 April 2019 Registered Direct/Private Placement Agent 1.93 240,130 April 5, 2024 September 2019 Offering Investors 0.77 2,793,297 September 27, 2024 September 2019 Offering Underwriter 1.12 194,358 September 27, 2024 February 2020 Exercise Agreement Agent 1.28 138,886 August 19, 2025 May 2020 Registered Direct Offering Investors 1.00 1,670,588 November 18, 2025 May 2020 Registered Direct Offering Agent 1.33 155,647 May 14, 2025 August 2020 Underwriter 1.31 201,967 August 10, 2025 January 2021 Private Placement Investors 1.23 3,091,192 July 27, 2026 January 2021 Private Placement Agent 1.62 351,623 July 27, 2026 February 2021 Offering Investors 1.70 20,580,283 February 19, 2026 February 2021 Offering Agent 1.88 2,506,396 February 19, 2026 38,235,864
Schedule of summary of common stock reserved for future issuances	Stock plan options outstanding 13,250,171 Stock plan shares available for future grants 35,000 Warrants outstanding 38,235,864 Total 51,521,035

Operating Lease (Tables)

Operating Lease (Tables)	3 Months Ended
	Dec. 31, 2022
Operating Lease [Abstract]
Schedule operating lease expense	Lease cost Three Months Ended Three Months Ended Operating lease cost $ 59,707 $ 59,705 Variable lease cost 1,158 — Total lease cost $ 60,865 $ 59,705 Other information Weighted-average remaining lease term - operating leases 2.8 Years 3.8 Years Weighted-average discount rate - operating leases 8.0 % 8.0 %
Schedule of lease liabilities due under the company’s non-cancellable leases	Year Ending September 30, December 31, 2023 (excluding the 3 months ended December 31, 2022) $ 183,427 2024 249,024 2025 253,883 2026 21,460 Total lease payments 707,794 Less: interest (77,048 ) Present value of lease liabilities $ 630,746
Schedule operating leases assets and liabilities	Leases Classification December 31, September 30, Assets Lease asset Operating $ 599,617 $ 646,074 Total lease assets $ 599,617 $ 646,074 Liabilities Current Operating $ 202,178 $ 196,989 Non-current Operating 428,568 481,245 Total lease liabilities $ 630,746 $ 678,234

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Dec. 31, 2022	Sep. 11, 2020
Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Shares owned (in Shares)		7,500,000
Acquisition value	$ 19,400,000
Revenue generation	40,000,000
Goodwill	$ 9,346,796
Delaware Corporation [Member]
Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Ownership, percentage		75%

Liquidity and Management's Pl_2

Liquidity and Management's Plan (Details)	3 Months Ended
	Dec. 31, 2022 USD ($)
Liquidity and Management's Plan [Abstract]
Negative cash flow operations	$ (4,824,439)
Working capital	$ 37,800,000

Patent and Technology License_2

Patent and Technology License Agreements (Details) - USD ($)		1 Months Ended				3 Months Ended
	Oct. 06, 2020	Jun. 30, 2022	Jan. 31, 2022	Jun. 30, 2021	Jan. 31, 2021	Dec. 31, 2022
Patent and Technology License Agreements (Details) [Line Items]
Maintenance fee		$ 90,000	$ 60,000	$ 90,000	$ 45,000
Annual minimum royalty payment						$ 100,000
Increasing annual royalties						25,000
Maximum aggregate annual royalties						150,000
Payable amount to NAT						$ 1,100,000
Agreement expiration date						Jan. 02, 2034
Developmental milestone, description						NoveCite is obligated to pay Novellus up to $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) the date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Eterna an amount equal to a mid-twenties percentage of any sublicensee fees it receives.
Revenue percentage						50%
Description of license agreement						The term of the license agreement will continue until (i) if there has not been a commercial sale of a licensed product in the territory, until the 10-year anniversary of the original license effective date, March 30, 2016, or (ii) if there has been a first commercial sale of a licensed product in the territory within the 10-year anniversary of the original license effective date, the 10-year anniversary of the first commercial sale on a country-by-country basis. The term of the license may be extended for additional 10-year periods for all countries in the territory by notifying Eisai and paying an extension fee equal to $10 million.
License agreement development, description						Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a biologics license application (“BLA”) for I/ONTAK.
Patent and Technology [Member]
Patent and Technology License Agreements (Details) [Line Items]
Description of annual maintenance fee						The annual maintenance fee increases by $15,000 per year up to a maximum of $90,000. Annual maintenance fees cease on the first sale of product. We also must pay up to an aggregate of $2.1 million in milestone payments, contingent on the achievement of various regulatory and commercial milestones. Under the terms of the license agreement, we also must pay a royalty of mid- to upper-single digit percentages of net sales, depending on the amount of annual sales, and subject to downward adjustment to lower- to mid-single digit percentages in the event there is no valid patent for the product in the United States at the time of sale. After the first sale of product, we will owe an annual minimum royalty payment of $100,000 that will increase annually by $25,000 for the duration of the term.
NoveCite [Member]
Patent and Technology License Agreements (Details) [Line Items]
Research and development expense	$ 5,000,000
Outstanding equity	25%
Percentage of outstanding equity						75%
Percentage of ownership additional shares						25%
Eisai [Member]
Patent and Technology License Agreements (Details) [Line Items]
Description of license agreement						Citius paid $40 million upfront payment which represents the acquisition date fair value of the in-process research and development acquired from Dr. Reddy’s. Dr. Reddy’s is entitled to up to $40 million in development milestone payments related to CTCL approvals in the U.S. and other markets, up to $70 million in development milestones for additional indications, as well as commercial milestone payments and low double-digit tiered royalties on net product sales, and up to $300 million for commercial sales milestones. We also must pay on a fiscal quarter basis tiered royalties equal to low double-digit percentages of net product sales. The royalties will end on the earlier of (i) the 15-year anniversary of the first commercial sale of the latest indication that received regulatory approval in the applicable country and (ii) the date on which a biosimilar product results in the reduction of net sales in the applicable product by 50% in two consecutive quarters, as compared to the four quarters prior to the first commercial sale of the biosimilar product.

Common Stock, Stock Options a_3

Common Stock, Stock Options and Warrants (Details) - USD ($)							3 Months Ended
	Nov. 08, 2022	Oct. 04, 2022	Sep. 13, 2022	Nov. 02, 2021	Nov. 01, 2021	Oct. 11, 2021	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 11, 2020
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock plus							2,000,000
Remaining shares											7,500,000
Shares available for future grants							35,000
Contractual term							10 years
Issued shares of purchase	50,000	50,000				375,000
Share price (in Dollars per share)	$ 1.04	$ 1.25				$ 2.04	$ 0.97
Options vest over terms							10 years
Board of directors granted options to purchase shares					200,000
Granted options to purchase value					$1.87
Share issued price per share								1.72
Stock-based compensation expense description							Stock-based compensation expense for the three months ended December 31, 2022 and 2021 was $1,201,081 (including $33,333 for the NoveCite Stock Plan) and $904,604 (including $33,333 for the NoveCite Stock Plan), respectively.
Citius stock plans (in Dollars)							$ 7,877,302
Weighted average period term							2 years 1 month 6 days
Common shares outstanding								2,000,000
Stock option plan , description								As of December 31, 2022, NoveCite has options outstanding to purchase 2,000,000 common shares at a weighted average exercise price of $0.24 per share, of which 1,251,111 are exercisable. All of these options vest over 36 months and have a term of 10 years. The weighted average remaining contractual term of options outstanding under the NoveCite Stock Plan is 8.1 years. At December 31, 2022, unrecognized total compensation cost related to unvested awards under the NoveCite Stock Plan of $149,777 is expected to be recognized over a weighted average period of 1.2 years.
Board of Directors [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Issued shares of purchase		3,375,000				2,515,000
Registered Direct Offering [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock offerings, description				the Company issued 50,201 shares of common stock for investor relations services and expensed the $95,884 fair value of the common stock issued.On March 21, 2022, the Company issued 100,000 shares of common stock for media, public and investor relations services and expensed the $178,000 fair value of the common stock issued.
2014 Stock Incentive Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock for issuance							866,667
Shares outstanding							855,171
2018 Omnibus Stock Incentive Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock for issuance							2,000,000
Number of shares outstanding							1,820,000
2020 Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock plus							3,110,000
Shares for issuance to employee reserved							8,740,000
2021 Omnibus Stock Incentive Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Option to purchase share outstanding							1,870,000
Remaining shares							1,240,000
2021 Stock Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Option to purchase share outstanding								8,705,000
Shares available for future grants								35,000
2023 Stock Plan [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Common stock plus							12,000,000
Common stock shares (in Dollars)							$ 35,000
Options vest over terms of 12 to 36 months [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Options vest over terms							10 years
Common Stock [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Issued shares			81,500
Fair value of common stock (in Dollars)			$ 104,320
Shares outstanding							146,211,130	146,029,630	146,211,130	145,979,429
Issued shares of purchase		375,000				175,000
Warrants [Member]
Common Stock, Stock Options and Warrants (Details) [Line Items]
Weighted average remaining life of the outstanding warrants								2 years 7 months 6 days
Aggregate intrinsic value for the warrants outstanding (in Dollars)								$ 55,866

Common Stock, Stock Options a_4

Common Stock, Stock Options and Warrants (Details) - Schedule of summary of option activity under our stock option plans	3 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Schedule Of Summary Of Option Activity Under Our Stock Option Plans Abstract
Option Shares at beginning | shares	9,400,171
Outstanding Weighted- Average Exercise Price at beginning | $ / shares	$ 2.07
Outstanding Weighted- Average Remaining Contractual Term at beginning	7 years 9 months 21 days
Outstanding Aggregate Intrinsic Value at beginning | $	$ 869,509
Granted Shares | shares	3,850,000
Granted Weighted- Average Exercise Price | $ / shares	$ 1.25
Option Shares , Exercised | shares
Exercised , Weighted- Average Exercise Price | $ / shares
Forfeited or expired Shares | shares
Forfeited or expired Weighted- Average Exercise Price | $ / shares
Option Shares at ending | shares	13,250,171
Outstanding Weighted- Average Exercise Price at ending | $ / shares	$ 1.83
Outstanding Weighted- Average Remaining Contractual Term at ending	8 years 2 months 12 days
Outstanding Aggregate Intrinsic Value at ending | $	$ 169,237
Exercisable Shares | shares	6,057,254
Exercisable Weighted- Average Exercise Price | $ / shares	$ 2.18
Exercisable Weighted- Average Remaining Contractual Term	6 years 11 months 15 days
Exercisable Aggregate Intrinsic Value | $	$ 169,237

Common Stock, Stock Options a_5

Common Stock, Stock Options and Warrants (Details) - Schedule of reserved shares of common stock for the exercise of outstanding warrants	3 Months Ended
	Dec. 31, 2022 $ / shares shares
Class of Warrant or Right [Line Items]
Number	38,235,864
December 2017 Registered Direct/Private Placement Offering Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 4.63
Number	640,180
Expiration Dates	June 19, 2023
March 2018 Registered Direct/Private Placement Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 2.86
Number	218,972
Expiration Dates	October 2, 2023
March 2018 Registered Direct/Private Placement Offering Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 3.73
Number	46,866
Expiration Dates	March 28, 2023
August 2018 Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.15
Number	3,921,569
Expiration Dates	August 14, 2023
August 2018 Offering Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.59
Number	189,412
Expiration Dates	August 8, 2023
April 2019 Registered Direct/Private Placement Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.42
Number	1,294,498
Expiration Dates	April 5, 2024
April 2019 Registered Direct/Private Placement Offering Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.93
Number	240,130
Expiration Dates	April 5, 2024
September 2019 Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 0.77
Number	2,793,297
Expiration Dates	September 27, 2024
September 2019 Offering Underwriter [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.12
Number	194,358
Expiration Dates	September 27, 2024
February 2020 Exercise Agreement Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.28
Number	138,886
Expiration Dates	August 19, 2025
May 2020 Registered Direct Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1
Number	1,670,588
Expiration Dates	November 18, 2025
May 2020 Registered Direct Offering Placement Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.33
Number	155,647
Expiration Dates	May 14, 2025
August 2020 Underwriter [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.31
Number	201,967
Expiration Dates	August 10, 2025
January 2021 Private Placement Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.23
Number	3,091,192
Expiration Dates	July 27, 2026
January 2021 Private Placement Offering Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.62
Number	351,623
Expiration Dates	July 27, 2026
February 2021 Registered Direct Offering Investors [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.7
Number	20,580,283
Expiration Dates	February 19, 2026
February 2021 Registered Direct Offering Agent [Member]
Class of Warrant or Right [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 1.88
Number	2,506,396
Expiration Dates	February 19, 2026

Common Stock, Stock Options a_6

Common Stock, Stock Options and Warrants (Details) - Schedule of summary of common stock reserved for future issuances	3 Months Ended
	Dec. 31, 2022 shares
Schedule Of Summary Of Common Stock Reserved For Future Issuances Abstract
Stock plan options outstanding	13,250,171
Stock plan shares available for future grants	35,000
Warrants outstanding	38,235,864
Total	51,521,035

Operating Lease (Details)

Operating Lease (Details) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Lease [Abstract]
Lease liability interest expenses	$ 13,250	$ 16,826

Operating Lease (Details) - Sch

Operating Lease (Details) - Schedule operating lease expense - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Operating Lease Expense [Abstract]
Operating lease cost	$ 59,707	$ 59,705
Variable lease cost	1,158
Total lease cost	$ 60,865	$ 59,705
Other information
Weighted-average remaining lease term - operating leases	2 years 9 months 18 days	3 years 9 months 18 days
Weighted-average discount rate - operating leases	8%	8%

Operating Lease (Details) - S_2

Operating Lease (Details) - Schedule of lease liabilities due under the company’s non-cancellable leases	Dec. 31, 2022 USD ($)
Schedule Of Lease Liabilities Due Under The Company's Non Cancellable Leases [Abstract]
2023 (excluding the 3 months ended December 31, 2022)	$ 183,427
2024	249,024
2025	253,883
2026	21,460
Total lease payments	707,794
Less: interest	(77,048)
Present value of lease liabilities	$ 630,746

Operating Lease (Details) - S_3

Operating Lease (Details) - Schedule operating leases assets and liabilities - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Assets
Lease asset	$ 599,617	$ 646,074
Total lease assets	599,617	646,074
Liabilities
Current	202,178	196,989
Non-current	428,568	481,245
Total lease liabilities	$ 630,746	$ 678,234

Gain on Sale of New Jersey Ne_2

Gain on Sale of New Jersey Net Operating Losses (Details)	3 Months Ended
	Dec. 31, 2022 USD ($)
Gain on Sale of New Jersey Net Operating Losses [Abstract]
Recognized a gain	$ 3,585,689

Subsequent Events (Details)

Subsequent Events (Details)	Dec. 31, 2022 shares
Subsequent Events [Abstract]
Reserved shares	12,000,000
Remaining shares	35,000
Maximum shares	12,035,000